InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,346.56
(
-1.84%
)
US TECH 100
17,912.00
(
-2.58%
)
Dow Jones
39,737.26
(
-1.51%
)
Brent Oil
77.36
(
-3.27%
)
Bitcoin
61,960.00
(
-5.19%
)
Post# of 15812
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

WiseFool

Send PM Follow Ignore
Followers 4
Posts 121
Boards Moderated 0
Alias Born 08/10/2005

WiseFool

Re: None

Thursday, 09/03/2015 4:46:52 PM

Thursday, September 03, 2015 4:46:52 PM

Post# of 15812
Very good read on OPKO’s out-licensed Rolapitant and how it could give Merck's Drug Emend a run for it's Money...

I’m not telling you it’s going to be easy – I’m telling you it’s going to be worth it
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent OPK News
More OPK News
InvestorsHub NewsWire

Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM

POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM

Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM

VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM

Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM

Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM

Start posting your company's news
Only $200 per official company press release!